Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
Menu bar   Go to the Portal


Clinician's brief
Volume 19 | Issue 8 (Nov-Dec 2021)

Ischemic Dermatopathy in Dogs

Clin Brief. Nov-Dec 2021;19(8):. 15 Refs
Paul Bloom1
1 Allergy, Skin and Ear Clinic for Pets, Livonia, MI 48154, USA.

Author Abstract

Decode, diagnose, and treat your next case of ischemic dermopathy with confidence after reviewing this primer.

Article Tools:
   Email to me

Archives Highlights:
Xanthinuria secondary to allopurinol treatment in dogs with leishmaniosis: Current perspectives of the Iberian veterinary community.
Of two-hundred and thirty respondents, 99.6% prescribe allopurinol for canine leishmaniosis. Xanthinuria was estimated to happen in less than one out of every four dogs by 91.7% of the clinicians. Three out of every four respondents inform owners about deleterious effects of allopurinol, and 28.4% consider implementing a change in diet in advance of treatment as a proactive measure. When xanthinuria is detected, 43.2% of the respondents discontinue allopurinol, 24% replace it by nucleotide-analogs, 14.9% reduce its dosage, and 3.1% split its dosage but increase administration frequency.
Effective recruitment advertising: using an evidence-based approach
It is no secret that the veterinary profession is going through a ‘recruitment crisis’, with many practices struggling to fill positions. This article examines some of the research on what actually works in recruitment advertising, and offers some evidence-based advice on the most effective way to attract appropriate applicants to apply to a vacancy.
Canine Pelvic Limb Amputation
Some amputations are necessary due to the pet owner’s financial constraints. However, surgeons are encouraged to exhaust all options prior to limb amputation while also educating owners about the risks, complications, and prognosis for each specific clinical case.
Clinical Efficacy and Safety of Malarone®, Azithromycin and Artesunate Combination for Treatment of Babesia gibsoni in Naturally Infected Dogs.
The dogs received combined therapy with Malarone (13.5 mg/kg PO q24 h), azithromycin (10 mg/kg PO q24 h), and artesunate (12.5 mg/kg PO q24 h) for 10 days. The combined treatment improved hematology and biochemical parameters to the reference range gradually during the first 14 days, resulting in stable values until day 56 after treatment. No clinically apparent adverse effects were reported during treatment and monitoring. No relapses of parasitemia were detected in control days 180, 360, 540, and 720 in all dogs.
Diagnostic value of liver function tests and ultrasonography in dogs with suspected congenital portosystemic shunts.
Fasting ammonia (FA) had the best combined sensitivity and specificity (77.4 and 93.3%, respectively) to diagnose congenital portosystemic shunt (cPSS). The sensitivity and negative predictive value were 100.0% for paired serum bile acids (SBA), making paired SBA the best test to exclude cPSS in this population. Sensitivity and specificity of abdominal ultrasound were 80.8 and 90.0%, respectively.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Ischemic Dermatopathy in ...
Contact Us